These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12690374)

  • 21. Side-effect profile of brimonidine tartrate in children.
    Al-Shahwan S; Al-Torbak AA; Turkmani S; Al-Omran M; Al-Jadaan I; Edward DP
    Ophthalmology; 2005 Dec; 112(12):2143. PubMed ID: 16225927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Alpha-2 adrenergic agonists in the treatment of glaucoma].
    Apătăchioae I; Chiseliţă D
    Oftalmologia; 1999; 47(2):35-40. PubMed ID: 10641099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brimonidine and pupillary diameter.
    Mastropasqua L; Carpineto P; Ciancaglini M
    Ophthalmology; 1998 Aug; 105(8):1352-3. PubMed ID: 9709738
    [No Abstract]   [Full Text] [Related]  

  • 24. Anterior uveitis as a side effect of topical brimonidine.
    Byles DB; Frith P; Salmon JF
    Am J Ophthalmol; 2000 Sep; 130(3):287-91. PubMed ID: 11020406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma.
    Gill K; Bayart C; Desai R; Golden A; Raimer P; Tamburro J
    Pediatr Dermatol; 2016 Jul; 33(4):e232-4. PubMed ID: 27282306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma.
    Sebastiani A; Parmeggiani F; Costagliola C; Ciancaglini M; D'Oronzo E; Mastropasqua L
    Acta Ophthalmol Scand Suppl; 2002; 236():29-30. PubMed ID: 12390124
    [No Abstract]   [Full Text] [Related]  

  • 27. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
    Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S;
    Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pupillographic, tonographic and refractive parameter changes after topical instillation of Brimonidine tartrate 0.2% in healthy subjects.
    Brogliatti B; Bogetto C; Prandi B; Boles Carenini B
    Acta Ophthalmol Scand Suppl; 1998; (227):34-5. PubMed ID: 9972337
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
    Schadlu R; Maus TL; Nau CB; Brubaker RF
    Arch Ophthalmol; 1998 Nov; 116(11):1441-4. PubMed ID: 9823343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of glaucoma with brimonidine (Alphagan 0.2%)].
    Detry-Morel M; Dutrieux C
    J Fr Ophtalmol; 2000 Oct; 23(8):763-8. PubMed ID: 11033496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma.
    Loon SC; Liew G; Fung A; Reid SE; Craig JC
    Clin Exp Ophthalmol; 2008 Apr; 36(3):281-9. PubMed ID: 18412600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
    thoe Schwartzenberg GW; Buys YM
    Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of topical clonidine versus brimonidine on choroidal blood flow and intraocular pressure during squatting.
    Weigert G; Resch H; Garhofer G; Fuchsjäger-Mayrl G; Schmetterer L
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4220-5. PubMed ID: 17724210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
    Chen TC
    J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children.
    Bowman RJ; Cope J; Nischal KK
    Eye (Lond); 2004 Jan; 18(1):24-6. PubMed ID: 14707960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for visual field progression in the low-pressure glaucoma treatment study.
    De Moraes CG; Liebmann JM; Greenfield DS; Gardiner SK; Ritch R; Krupin T;
    Am J Ophthalmol; 2012 Oct; 154(4):702-11. PubMed ID: 22835512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Depression of respiration via toxic effects on the central nervous system following use of topical brimonidine in an infant with congenital glaucoma].
    Heimann K; Peschgens T; Merz U; Hoernchen H; Wenzl T
    Ophthalmologe; 2007 Jun; 104(6):505-7. PubMed ID: 17334744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment].
    Titouamane S; Baudouin C
    J Fr Ophtalmol; 2002 Jun; 25(6):568-75. PubMed ID: 12223942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exposure to topical apraclonidine in children with glaucoma.
    Wright TM; Freedman SF
    J Glaucoma; 2009; 18(5):395-8. PubMed ID: 19525731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The ocular hypotensive effect and safety of 0.2% brimonidine].
    Yu M; Li Y; Ge J
    Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.